| A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, (NCT03138499) | Bristol-Myers Squibb | 2017-06-26 |
| Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices (NCT02856646) | Bristol-Myers Squibb | 2016-10-07 |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies (NCT02639559) | Washington University School of Medicine | 2016-03-31 |
| Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation (NCT02087657) | University of Kansas Medical Center | 2014-03-01 |
| Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination (NCT02007811) | University of Erlangen-Nürnberg Medical School | 2013-11-01 |
| Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant (NCT01904175) | Duke University | 2013-08-01 |
| P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies (NCT01854567) | Mesoblast, Ltd. | 2013-08-01 |
| A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor (NCT01696461) | Center for International Blood and Marrow Transplant Research | 2013-05-01 |
| Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE (NCT01555892) | Baylor College of Medicine | 2013-01-14 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease (NCT01458288) | GPCR Therapeutics, Inc. | 2012-10-01 |
| Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases (NCT01336712) | Northside Hospital, Inc. | 2011-04-01 |
| A Study Of Panobinostat In Children With Refractory Hematologic Malignancies (NCT01321346) | Therapeutic Advances in Childhood Leukemia Consortium | 2011-03-01 |
| Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation (NCT01283776) | University of Cologne | 2011-03-01 |
| Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies (NCT01221857) | Gamida Cell ltd | 2010-11-01 |
| Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies (NCT01188798) | St. Jude Children's Research Hospital | 2010-09-01 |
| MSC and HSC Coinfusion in Mismatched Minitransplants (NCT01045382) | University of Liege | 2010-07-01 |
| Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic (NCT01833884) | Centre Henri Becquerel | 2010-04-01 |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy (NCT00990587) | University Health Network, Toronto | 2009-10-01 |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer (NCT00975975) | Indiana University | 2009-09-01 |
| Host Dendritic Cells in Allograft Patients (NCT00935597) | Icahn School of Medicine at Mount Sinai | 2009-08-01 |
| Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial (NCT00924131) | National Cancer Institute (NCI) | 2009-04-17 |
| Umbilical Cord Blood Transplant for Hematological Malignancies (NCT00891592) | University of Pennsylvania | 2009-01-01 |
| Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas (NCT00685997) | UMC Utrecht | 2008-06-01 |
| Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma (NCT00705250) | Memorial Sloan Kettering Cancer Center | 2008-06-01 |
| A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies (NCT01315132) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2008-04-10 |
| Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) (NCT00667615) | Memorial Sloan Kettering Cancer Center | 2008-04-01 |
| Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT (NCT00648037) | Memorial Sloan Kettering Cancer Center | 2008-03-01 |
| Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant (NCT00597714) | David Rizzieri, MD | 2008-02-01 |
| Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant (NCT00674427) | University of Pennsylvania | 2008-01-01 |
| Investigation of the Cylex® ImmuKnow® Assay (NCT00569842) | Indiana University | 2007-11-01 |
| Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). (NCT00665314) | Genzyme, a Sanofi Company | 2007-11-01 |
| Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma (NCT00484874) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2007-06-01 |
| Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies (NCT00460694) | Singapore General Hospital | 2006-08-01 |
| Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) (NCT00368082) | Baylor College of Medicine | 2006-04-01 |
| A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma (NCT00343564) | Cytokinetics | 2006-04-01 |
| Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation (NCT00698685) | University of Arizona | 2006-01-23 |
| Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies (NCT00256191) | Cortice Biosciences, Inc. | 2005-11-01 |
| A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease (NCT00284804) | Bristol-Myers Squibb | 2005-11-01 |
| Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children (NCT00552825) | Sheba Medical Center | 2005-10-01 |
| Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies (NCT00150462) | Amgen | 2005-09-01 |
| Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants (NCT00606437) | Duke University | 2005-09-01 |
| Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus (NCT00133367) | Massachusetts General Hospital | 2005-08-01 |
| Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease (NCT00165412) | Dana-Farber Cancer Institute | 2005-07-01 |
| Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease (NCT00385788) | M.D. Anderson Cancer Center | 2005-07-01 |
| Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease (NCT00129753) | M.D. Anderson Cancer Center | 2005-06-22 |
| Quality of Life Among Survivors of Hodgkin Lymphoma (NCT00598728) | Memorial Sloan Kettering Cancer Center | 2005-05-01 |
| Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies (NCT00990717) | University Health Network, Toronto | 2005-03-01 |
| Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkin's Disease and Lymphoma Malins High Grade (NCT00551798) | University Hospital, Limoges | 2005-03-01 |
| Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies (NCT00718757) | St. Jude Children's Research Hospital | 2005-01-01 |
| Behavioral Intervention For BMT/SCT Survivors (NCT00579917) | Memorial Sloan Kettering Cancer Center | 2005-01-01 |
| Psychosocial Impact of Cancer-Related Female Infertility (NCT00386217) | M.D. Anderson Cancer Center | 2004-12-01 |
| AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease (NCT00396201) | Genzyme, a Sanofi Company | 2004-11-01 |
| Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies (NCT00131014) | Dana-Farber Cancer Institute | 2004-08-09 |
| Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma (NCT00147875) | University of Cologne | 2004-03-01 |
| Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation (NCT00165425) | Dana-Farber Cancer Institute | 2004-02-01 |
| Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation (NCT00144677) | Dana-Farber Cancer Institute | 2003-11-01 |
| Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease (NCT00209014) | Emory University | 2003-07-01 |
| Amifostine for Head and Neck Irradiation in Lymphoma (NCT00136474) | Dana-Farber Cancer Institute | 2003-05-01 |
| Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy (NCT01085058) | WiSP Wissenschaftlicher Service Pharma GmbH | 2003-05-01 |
| Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF (NCT00952237) | Dartmouth-Hitchcock Medical Center | 2003-01-01 |
| Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma (NCT00232440) | University Health Network, Toronto | 2003-01-01 |
| Efficacy Study of Outpatient Therapy for Lymphoma (NCT00163761) | Bayside Health | 2002-12-01 |
| Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation (NCT00144703) | Dana-Farber Cancer Institute | 2002-07-01 |
| T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies (NCT00683046) | University of Chicago | 2001-11-01 |
| Stem Cell Transplant for Hematological Malignancy (NCT00176930) | Masonic Cancer Center, University of Minnesota | 2001-10-01 |
| Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy (NCT00165438) | Dana-Farber Cancer Institute | 2001-10-01 |
| The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen (NCT01890486) | Wake Forest University Health Sciences | 2001-05-21 |
| CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation (NCT00038818) | M.D. Anderson Cancer Center | 2001-05-01 |
| Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors (NCT00165308) | Dana-Farber Cancer Institute | 2001-04-01 |
| Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma (NCT00163748) | Bayside Health | 2001-02-01 |
| Allogeneic Transplantation From Related Haploidentical Donors (NCT00185692) | Stanford University | 2000-08-01 |
| Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies (NCT01499147) | University of Illinois at Chicago | 2000-02-01 |
| Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants (NCT00001830) | National Cancer Institute (NCI) | 1999-07-20 |
| Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors (NCT00179816) | Ann & Robert H Lurie Children's Hospital of Chicago | 1999-04-01 |
| Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease (NCT00398177) | Stanford University | 1999-01-01 |
| Allogeneic Blood Stem Cell Transplantation (NCT00423709) | M.D. Anderson Cancer Center | 1998-01-01 |
| Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia (NCT00001575) | National Cancer Institute (NCI) | 1997-04-01 |
| Spectroscopy With Surface Coils and Decoupling (NCT00581815) | Memorial Sloan Kettering Cancer Center | 1997-02-01 |
| A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942) (NCT00592111) | Memorial Sloan Kettering Cancer Center | 1996-03-01 |
| Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers (NCT00608452) | Memorial Sloan Kettering Cancer Center | 1995-07-01 |
| A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas (NCT00001430) | National Cancer Institute (NCI) | 1995-02-01 |
| Mantle Irradiation for Hodgkin's Disease (NCT00165269) | Dana-Farber Cancer Institute | 1992-05-01 |
| Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease (NCT00000626) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. (NCT00720603) | Genzyme, a Sanofi Company | |